Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NMTC NASDAQ:PROF NASDAQ:SGHT NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNMTCNeuroOne Medical Technologies$0.90+0.3%$0.68$0.40▼$1.39$44.76M0.66202,623 shs149,662 shsPROFProfound Medical$5.90+1.2%$5.83$3.89▼$11.42$175.21M0.4933,716 shs44,293 shsSGHTSight Sciences$3.56-5.8%$3.82$2.03▼$8.41$195.41M2.47148,442 shs63,416 shsTLSITriSalus Life Sciences$4.67-0.6%$5.18$3.50▼$6.04$177.84M0.5133,399 shs27,802 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNMTCNeuroOne Medical Technologies-12.78%+24.17%+35.65%+48.86%+8.24%PROFProfound Medical-0.68%+1.22%-3.00%+23.52%-46.07%SGHTSight Sciences+5.88%+7.69%-12.90%+14.89%-54.13%TLSITriSalus Life Sciences+4.44%-0.21%-11.15%-16.81%-17.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNMTCNeuroOne Medical Technologies2.1783 of 5 stars3.55.00.00.00.60.80.0PROFProfound Medical2.1524 of 5 stars3.52.00.00.00.62.50.6SGHTSight Sciences1.5946 of 5 stars2.12.00.00.01.73.30.6TLSITriSalus Life Sciences2.257 of 5 stars3.62.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNMTCNeuroOne Medical Technologies 3.00Buy$1.4560.86% UpsidePROFProfound Medical 3.00Buy$11.0086.44% UpsideSGHTSight Sciences 2.29Hold$3.9310.49% UpsideTLSITriSalus Life Sciences 3.25Buy$10.75130.19% UpsideCurrent Analyst Ratings BreakdownLatest NMTC, SGHT, PROF, and TLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.005/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025PROFProfound MedicalRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy5/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.005/5/2025NMTCNeuroOne Medical TechnologiesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.45(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNMTCNeuroOne Medical Technologies$3.45M13.02N/AN/A$0.03 per share30.05PROFProfound Medical$10.68M16.60N/AN/A$2.01 per share2.94SGHTSight Sciences$79.87M2.30N/AN/A$1.72 per share2.07TLSITriSalus Life Sciences$29.43M6.00N/AN/A($0.83) per share-5.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNMTCNeuroOne Medical Technologies-$12.32M-$0.22N/A∞N/A-75.41%-334.64%-124.42%8/13/2025 (Estimated)PROFProfound Medical-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/6/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%7/30/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.12N/AN/AN/A-84.67%N/A-111.63%8/13/2025 (Estimated)Latest NMTC, SGHT, PROF, and TLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43N/AN/AN/A$4.75 millionN/A8/13/2025Q2 2025TLSITriSalus Life Sciences-$0.22N/AN/AN/A$10.69 millionN/A8/7/2025Q2 2025SGHTSight Sciences-$0.25N/AN/AN/A$18.18 millionN/A5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/13/2025Q2 2025NMTCNeuroOne Medical Technologies-$0.09-$0.07+$0.02-$0.07$1.27 billion$1.39 billion5/8/2025Q1 2025PROFProfound Medical-$0.29-$0.36-$0.07-$0.36$4.78 million$2.62 million5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNMTCNeuroOne Medical TechnologiesN/A2.131.09PROFProfound Medical0.0911.3110.03SGHTSight Sciences0.5110.479.99TLSITriSalus Life SciencesN/A2.141.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNMTCNeuroOne Medical Technologies16.07%PROFProfound Medical47.86%SGHTSight Sciences55.51%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipNMTCNeuroOne Medical Technologies8.90%PROFProfound Medical1.52%SGHTSight Sciences30.90%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNMTCNeuroOne Medical Technologies2049.82 million45.38 millionOptionablePROFProfound Medical15030.05 million29.60 millionOptionableSGHTSight Sciences21051.70 million35.72 millionOptionableTLSITriSalus Life Sciences10637.84 million27.43 millionNot OptionableNMTC, SGHT, PROF, and TLSI HeadlinesRecent News About These CompaniesTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockJuly 24 at 5:58 PM | businesswire.comTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comTriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | businesswire.com3 Stocks With Robust Growth Outlooks Insiders Are Buying (TLSI)February 19, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?By Chris Markoch | July 11, 2025View CrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?The Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Kinder Morgan: At the Hotspot of the Natural Gas RevolutionBy Thomas Hughes | July 21, 2025View Kinder Morgan: At the Hotspot of the Natural Gas Revolution3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingNMTC, SGHT, PROF, and TLSI Company DescriptionsNeuroOne Medical Technologies NASDAQ:NMTC$0.90 +0.00 (+0.33%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.00 (+0.07%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Profound Medical NASDAQ:PROF$5.90 +0.07 (+1.20%) Closing price 03:59 PM EasternExtended Trading$5.84 -0.07 (-1.10%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Sight Sciences NASDAQ:SGHT$3.56 -0.22 (-5.82%) Closing price 04:00 PM EasternExtended Trading$3.56 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.TriSalus Life Sciences NASDAQ:TLSI$4.67 -0.03 (-0.64%) Closing price 04:00 PM EasternExtended Trading$4.64 -0.03 (-0.64%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
